Terms: = Ovarian cancer AND PICALM, CLTH, 8301, ENSG00000073921, CALM, Q13492
3 results:
1. Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m² versus 40 mg/m² in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial.
Motohashi T; Yabuno A; Michimae H; Ohishi T; Nonaka M; Takano M; Nishio S; Fujiwara H; Fujiwara K; Kondo E; Sugiyama T; Tabata T
J Gynecol Oncol; 2021 Jan; 32(1):e9. PubMed ID: 33185050
[TBL] [Abstract] [Full Text] [Related]
2. Mood states associated with transitory physical symptoms among breast and ovarian cancer survivors.
Badr H; Basen-Engquist K; Carmack Taylor CL; de Moor C
J Behav Med; 2006 Oct; 29(5):461-75. PubMed ID: 16705484
[TBL] [Abstract] [Full Text] [Related]
3. Presymptomatic testing for BRCA1 and BRCA2: how distressing are the pre-test weeks? Rotterdam/Leiden Genetics Working Group.
Lodder LN; Frets PG; Trijsburg RW; Meijers-Heijboer EJ; Klijn JG; Duivenvoorden HJ; Tibben A; Wagner A; van der Meer CA; Devilee P; Cornelisse CJ; Niermeijer MF
J Med Genet; 1999 Dec; 36(12):906-13. PubMed ID: 10593998
[TBL] [Abstract] [Full Text] [Related]
